CELONKO – "Development of modern biomarkers and development of an innovative FGFR kinase inhibitor" – the project received co-financing from the National Centre for Research and Development in the amount of PLN 39,025,710.
For many years Celon Pharma has been developing projects targeting selected cancer paths. CELONKO, with its objective being preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs), fits well into this scope of activities. As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight against stomach cancer, bladder cancer and in treatment of squamous cell lung cancer. Subsequent stages of the project will include the development of a diagnostic test for identifying patients with FGFR receptor aberrations. This will allow for selecting the patients who would benefit most from a personalised therapy based on a selective FGFR inhibitor.
The project is implemented by a scientific-business consortium lead by Celon Pharma along with the National Research Institute for Tuberculosis and Lung Diseases in Warsaw, the Military Institute of Medicine in Warsaw, the Maria Skłodowska-Curie Institute of Oncology in Warsaw and the Medical University of Gdańsk. The scientific institutions are responsible for the search for molecular pathways and diagnostic methods and their facilities will also carry out the clinical part of the project. Celon Pharma, as the consortium leader, is responsible for the issues related to regulation, quality and pharmaceutical aspects, as well as coordination of clinical trials conducted with the objective of obtaining the FGFR inhibitor.
Planned implementation of the project: 2015 – 2018
The total cost of the project is PLN 54,717,125.
NATco – "New anti-amyloid therapy for cognitive disorders" – the project received co-financing from the National Centre for Research and Development in the amount of PLN 4,100,000.
The objective of the "New anti-amyloid therapy for cognitive disorders" project is development of a new drug which would enhance the procognitive process and would be used in the treatment of i.a. Alzheimer's disease. The previous research hypotheses in the treatment of Alzheimer's disease introduced by pharmaceutical companies and research institutes have focused on amyloid beta. Projects which intended to prove that this protein is the only cause of Alzheimer's disease have failed. NAtco research focuses on 5-HT6 serotonin receptors. They can have beneficial effects on cognitive processes which are impaired in all sorts of dementias and thus improve the patients' condition.
The project is being implemented by Celon Pharma as part of a scientific-business consortium with research centres located in Kraków: Institute of Pharmacology of the Polish Academy of Sciences and the Jagiellonian University Medical College, which is the Consortium Leader. Both of these institutions are responsible for developing compounds, synthetic works and studies of bio-pharmacological studies. Celon Pharma S.A. serves a strategic role of an in the industrial partner in the project. The Company is responsible for conducting research and potential commercialisation of the drug.
Planned implementation of the project: 2015 – 2017
Total cost of the project: PLN 4,815,143
NoteSzHD – "New therapy in psychotic disorders and Huntington's disease with special focus on cognitive deficits" – the project received co-financing from the National Centre for Research and Development in the amount of PLN 26,730,836 under the STRATEGMED programme.
The project is being implemented by Celon Pharma in collaboration with five scientific partners: the Nencki Institute of Experimental Biology in the Polish Academy of Sciences, the Mossakowski Medical Research Centre
in the Polish Academy of Sciences, Institute of Pharmacology of the Polish Academy of Sciences, the Medical University of Lodz and the Poznan University of Medical Sciences. Celon Pharma is responsible for key activities associated with the development of the drug. The tasks of the remaining members of the consortium consist in exploration of mechanisms of action of phosphodiesterase 10A inhibitors (PDE10A).
Celon Pharma has conducted work on innovative PDE10A inhibitors since 2013. Additional support and interest from the scientific community is an opportunity to accelerate the pace of works on the drug to be used is psychotic disorders and Huntington's disease and to make the therapy available to patients.
Planned implementation of the project: 2015 – 2017
Total cost of the project: PLN 40,279,820
PIKCel – development of a technology in the treatment of asthma and COPD
The objective of the project is to confirm the therapeutic action of the PI3K inhibitor in patients with lung diseases such as asthma or chronic obstructive pulmonary disease (COPD). The planned route of administration of the drug is inhalation. The project involves actions taken in four stages, including preclinical and toxicological studies, drug formulation, as well as phase I and II clinical trials.
The project was launched in December 2015 and is planned to be finalised in June 2020, which is when phase IIa (proof-of-concept) clinical trials will be conducted.
The total value of the PIKCel project is PLN 23,508,985.88, of which PLN 15,373,271.42 will be received by the company under the Smart Growth Operational Programme.